Comparison of the cost to reach A1C targets in patients with type-2 diabetes mellitus on oral antidiabetic agents and either biphasic insulin aspart 70/30 or insulin glargine

被引：0

|

作者：

Cobden, D

Allen, E

Botteman, M

机构：

[1] PharMerit, Bethesda, MD USA

[2] Novo Nordisk Inc, Princeton, NJ USA

来源：

VALUE IN HEALTH | 2005年 / 8卷 / 03期

关键词：

D O I：

10.1016/S1098-3015(10)62953-1

中图分类号：

F [经济];

学科分类号：

02 ;

摘要：

引用

收藏

页码：358 / 358

页数：1

相关论文

共 50 条

[41] COST-EFFECTIVENESS OF INSULIN DEGLUDEC/ASPART VERSUS BIPHASIC INSULIN ASPART IN PATIENTS WITH TYPE 2 DIABETES IN IRAN
Saiyarsarai, P.
Khosroshahi, Ghazizadeh A.
Khedmati, J.
Ghaffari, S.
Soleymani, F.
Seyyedifar, M.
VALUE IN HEALTH, 2019, 22 : S576 - S576
[42] Starting patients with type 2 diabetes on insulin therapy using once-daily injections of biphasic insulin aspart 70/30, biphasic human insulin 70/30, or NPH insulin in combination with metformin
Kilo, C
Mezitis, N
Jain, R
Mersey, J
McGill, J
Raskin, P
JOURNAL OF DIABETES AND ITS COMPLICATIONS, 2003, 17 (06) : 307 - 313
[43] Insulin glargine in combination with oral antidiabetic drugs as a cost-equivalent alternative to conventional Insulin therapy in type 2 diabetes mellitus
Lechleitner, M
Roden, M
Haehling, E
Mueller, M
WIENER KLINISCHE WOCHENSCHRIFT, 2005, 117 (17) : 593 - 598
[44] Serum 1,5-anhydroglucitol as a marker of glycemic control in subjects receiving twice-daily biphasic insulin aspart 70/30 (BIAsp 70/30) vs. once-daily insulin glargine in patients with type 2 DM on oral antidiabetic agents
Moses, A
Raskin, P
Hu, P
Allen, E
DIABETES, 2005, 54 : A96 - A96
[45] Cost-effectiveness of biphasic insulin aspart 30 versus human premix insulin for type 2 diabetes patients in China
Lynch, M.
Scheijbeler, H.
Kotchie, R.
Neilsen, S.
White, J.
Valentine, W. J.
VALUE IN HEALTH, 2007, 10 (06) : A262 - A262
[46] Insulin Glargine Plus OHAs Versus Biphasic Insulin in Type 2 Diabetes-A Cost Comparison
Owens, David
Evans, Marc
Carroll, Dawn
Keech, Martin
DIABETES, 2009, 58 : A141 - A141
[47] Role of Oral Antidiabetic Agents in Type-2 Diabetes Mellitus Patients
Chohan, Raj Kumar
Kimar, Jagdesh
Murad, Shah
PAKISTAN JOURNAL OF MEDICAL & HEALTH SCIENCES, 2011, 5 (01): : 59 - 62
[48] Once daily initiation with biphasic insulin aspart 30 (BIAsp 30) versus insulin glargine in patients with type 2 diabetes inadequately controlled with oral drugs - a randomized controlled trial
Franek, E.
Kalra, S.
Pesic, M.
Smahelova, A.
Thomsen, H.
Strojek, K.
DIABETOLOGIA, 2009, 52 : S93 - S93
[49] Biphasic insulin aspart 70/30 vs. insulin glargine in insulin naive type 2 diabetes patients: modelling the long-term health economic implications in a Swedish setting
Goodall, G.
Jendle, J. H.
Valentine, W. J.
Munro, V.
Brandt, A. B.
Ray, J. A.
Roze, S.
Foos, V.
Palmer, A. J.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2008, 62 (06) : 869 - 876
[50] Comments on Long-term clinical and cost outcomes of treatment with biphasic insulin aspart 30/70 versus insulin glargine in insulin-naive type 2 diabetes patients:: cost-effectiveness analysis in the UK setting
Currie, CJ
McEwan, P
Poole, C
CURRENT MEDICAL RESEARCH AND OPINION, 2006, 22 (05) : 967 - 968

← 1 2 3 4 5 →